Oxytocin Reduces Pain by Boosting Natural Opioid Peptides in the Brain's Pain Control Center

What the researchers found

Four key findings emerged: (1) Pain stimulation increased PAG concentrations of oxytocin, leucine-enkephalin, methionine-enkephalin, and β-endorphin, but not dynorphin A(1-13). (2) Blocking oxytocin receptors in the PAG decreased levels of the three enkephalins/endorphin but not dynorphin. (3) The pain-relieving effect of oxytocin in the PAG was reversed by naloxone, an opioid receptor antagonist. (4) Exogenous oxytocin administration increased PAG levels of leucine-enkephalin, methionine-enkephalin, and β-endorphin, but not dynorphin.

Together, this demonstrates that oxytocin's pain-modulating role in the PAG is mediated through enkephalin and endorphin peptides, but not dynorphin.

Why it matters

Understanding how oxytocin reduces pain through the endogenous opioid system opens potential therapeutic avenues. If oxytocin can stimulate the brain's natural painkillers, it might provide pain relief without the addiction risk of synthetic opioids. The specific identification of which opioid peptides respond to oxytocin (enkephalins and β-endorphin, not dynorphin) provides molecular targets for future research.

How the study worked

Rats received PAG microdialysis catheterization to measure local peptide concentrations. Pain stimulation was applied while collecting perfusion fluid samples. Experiments tested the effects of intra-PAG oxytocin injection, oxytocin receptor antagonist, and the opioid antagonist naloxone on endogenous opioid peptide levels and pain thresholds. Peptide concentrations were measured by radioimmunoassay.

What this study cannot tell us

The study was conducted in rats using direct brain injections, which is not a clinically feasible delivery method. The PAG microdialysis technique measures local peptide concentrations but may not reflect broader brain-wide changes. The findings may not directly translate to human pain processing. Specific quantitative changes in peptide levels are not reported in the abstract.

How to read the evidence

This is a preclinical mechanistic study using PAG microdialysis in rats with pharmacological interventions. It provides strong mechanistic evidence for peptide-peptide interaction but is far from clinical application.

When this study was published

Published in 2011, this is a foundational study establishing the link between oxytocin and endogenous opioid peptides in pain modulation. The field has continued to explore this connection.

The bigger picture

This study bridges two major neuropeptide systems — oxytocin and endogenous opioids — in pain regulation. It helps explain why social bonding and touch (which release oxytocin) can reduce pain, and suggests that oxytocin-based interventions could complement or partially replace opioid therapies. The selective involvement of specific opioid peptides adds nuance to our understanding of the brain's pain control hierarchy.

Questions still open

• Could intranasal oxytocin increase endogenous opioid levels in the PAG to provide non-addictive pain relief in humans?
• Why does oxytocin selectively influence enkephalins and β-endorphin but not dynorphin?
• Does the oxytocin-opioid interaction in the PAG explain why social support reduces pain perception in humans?

Common questions

Read the original research

Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides.

Peptides, 32(6), 1255-61

Citation

Yang, Jun; Liang, Jin-Ying; Li, Peng; Pan, Yan-Juan; Qiu, Pei-Yong; Zhang, Jing; Hao, Fang; Wang, Da-Xin. (2011). Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides.. Peptides, 32(6), 1255-61. https://doi.org/10.1016/j.peptides.2011.03.007